The present study further defines Lck as a relevant target in CLL, and shows that inhibition of this SFK causes effects similar to those observed when CLL cells are treated with the phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitor idelalisib. This evidence concerns the gene LCK and B-cell chronic lymphocytic leukemia.